First-line pembrolizumab monotherapy for PD-L1-positive (TPS >= 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort-ESCKEYP trial (GFPC 05-2018).
Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: First-line pembrolizumab monotherapy for PD-L1-positive (TPS >= 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort-ESCKEYP trial (GFPC 05-2018). ### Output: Pembrolizumab